Sociedad Americana de Hirudoterapia

Periprocedural bridging anticoagulation: current perspectives.

Research article published in American journal of therapeutics (2011)

Última actualización: June 18, 2026Revisado por: ASH Editorial Board
Research article — evidence reviewArticle reference
Evidence: Narrative reviewEnsayos clínicosPalaniswamy et al. · American journal of therapeutics, 2011

Abstract

Perioperative management of patients on chronic anticoagulant use involves balancing individual risk for thromboembolism and bleeding. Discontinuation of antithrombotic therapy can place patients at increased risk of thromboembolic complications, whereas continuing antithrombotic therapy can increase procedure-related bleeding risk. Temporary perioperative substitution of low-molecular weight heparin or unfractionated heparin in place of warfarin, "the bridge therapy" is often used in the periprocedural period, but the indications and timing of this is still uncertain. This review addresses the risk stratification of patients according to thromboembolic risk, indications, timing, and duration, and a practical approach to bridge therapy.

Abstract sourced from PubMed (NCBI) for the cited record. See the original publication for the authoritative version.

Publication typeJournal ArticleReview
Indexed MeSH termsAnticoagulantsBlood Loss, SurgicalHeparinHumansPerioperative CarePostoperative HemorrhageRisk AssessmentThromboembolismWarfarin

Resumen

Periprocedural bridging anticoagulation: current perspectives.

Por qué esto importa para la hirudoterapia

This review addresses the risk stratification, indications, timing, and practical approaches to periprocedural bridging anticoagulation, which involves substituting heparin for warfarin temporarily. It focuses on balancing the risks of thromboembolism and procedure-related bleeding during invasive procedures. There is no defensible link to hirudotherapy, the leech secretome, or the American Society of Hirudotherapy's domain. The abstract focuses strictly on conventional medical management with warfarin and heparin. No leeches, hirudin, or related therapies are mentioned or implied in the text, making it entirely irrelevant to the society's focus.

Citación

Periprocedural bridging anticoagulation: current perspectives.

Palaniswamy et al. · American journal of therapeutics, 2011

Contexto clínico relacionado

Añadido a la biblioteca ASH: May 28, 2026 · Última actualización del sitio: June 18, 2026

Este sitio web proporciona información educativa y no constituye consejo médico, diagnóstico ni recomendaciones de tratamiento. La terapia con sanguijuelas medicinales conlleva riesgos clínicamente significativos y debe ser realizada únicamente por profesionales calificados bajo protocolos aprobados institucionalmente. La autorización 510(k) de la FDA para sanguijuelas medicinales se limita a indicaciones específicas; las discusiones sobre uso investigativo y fuera de indicación se señalan correspondientemente. Para orientación médica específica, consulte a un profesional de salud calificado.